Judy L Aschner

Dr. Judy L Aschner

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
CMCynthia T. McEvoy
Cynthia T. McEvoy
LJLucky Jain
Lucky Jain
BSBarbara Schmidt
Barbara Schmidt
SASteven Abman
Steven Abman
EBEduardo Bancalari
Eduardo Bancalari
JAJudy L Aschner
Judy L Aschner
Bronchopulmonary dysplasia (BPD) is the most common complication of extreme preterm birth. Infants who develop BPD manifest aberrant or arrested pulmonary development and can experience lifelong alterations in cardiopulmonary function. Despite decades of promising research, primary prevention of BPD has proven elusive. This workshop report identifies current barriers to the conduct of primary prevention studies for BPD and causal pathways implicated in BPD pathogenesis. Throughout, we highlight promising areas for research to improve understanding of normal and aberrant lung development, distinguish BPD endotypes, and ascertain biomarkers for more targeted therapeutic approaches to prevention. We conclude with research recommendations and priorities to accelerate discovery and promote lung health in infants born preterm.

1 December 2015 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
JAJudy L Aschner
Judy L Aschner
AAAdam Anderson
Adam Anderson
JSJames Christopher Slaughter
James Christopher Slaughter
MAMichael Aschner
Michael Aschner
SSSteven Steele
Steven Steele
NMNathalie Maitre
Nathalie Maitre
Background: Manganese, an essential metal for normal growth and development, is neurotoxic on excessive exposure. Standard trace element–supplemented

26 May 2014 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
CFCandice D. Fike
Candice D. Fike
MSMarshall Summar
Marshall Summar
JAJudy L Aschner
Judy L Aschner

1 October 2017 in The Journal of Pediatrics
Verified
Journal Article
Closed access
JAJudy L Aschner
Judy L Aschner
EBEduardo H. Bancalari
Eduardo H. Bancalari
CMCynthia T. McEvoy
Cynthia T. McEvoy

28 March 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CFCandice D. Denise Fike
Candice D. Denise Fike
JAJudy L Aschner
Judy L Aschner
Approximately 8–42% of premature infants with chronic lung disease of prematurity, bronchopulmonary dysplasia (BPD), develop pulmonary hypertension (PH). Infants with BPD-PH carry alarmingly high mortality rates of up to 47%. Effective PH-targeted pharmacotherapies are desperately needed for these infants. Although many PH-targeted pharmacotherapies are commonly used to treat BPD-PH, all current use is off-label. Moreover, all current recommendations for the use of any PH-targeted therapy in infants with BPD-PH are based on expert opinion and consensus statements. Randomized Control Trials (RCTs) are needed to determine the efficacy of PH-targeted treatments in premature infants with or at risk of BPD-PH. Prior to performing efficacy RCTs, studies need to be conducted to obtain pharmacokinetic, pharmacodynamic, and safety data for any pharmacotherapy used in this understudied and fragile patient population. This review will discuss current and needed treatment strategies, identify knowledge deficits, and delineate both challenges to be overcome and approaches to be taken to develop effective PH-targeted pharmacotherapies that will improve outcomes for premature infants with or at risk of developing BPD-PH.

22 December 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
MNMakiko Nanishi
Makiko Nanishi
ACAruna Chandran
Aruna Chandran
XLXiuhong Li
Xiuhong Li
JSJoseph B. Stanford
Joseph B. Stanford
AAAkram Alshawabkeh
Akram Alshawabkeh
KHKohei Hasegawa
Kohei Hasegawa
Objective: Many studies have shown that severe (hospitalized) bronchiolitis during infancy is a risk factor for developing childhood asthma. However, the population subgroups at the highest risk remain unclear. Using large nationwide pediatric cohort data, namely the NIH Environmental influences on Child Health Outcomes (ECHO) Program, we aimed to quantify the longitudinal relationship of bronchiolitis hospitalization during infancy with asthma in a generalizable dataset and to examine potential heterogeneity in terms of major demographics and clinical factors. Methods: We analyzed data from infants (age <12 months) enrolled in one of the 53 prospective cohort studies in the ECHO Program during 2001–2021. The exposure was bronchiolitis hospitalization during infancy. The outcome was a diagnosis of asthma by a physician by age 12 years. We examined their longitudinal association and determined the potential effect modifications of major demographic factors. Results: The analytic cohort consisted of 11,762 infants, 10% of whom had bronchiolitis hospitalization. Overall, 15% subsequently developed asthma. In the Cox proportional hazards model adjusting for 10 patient-level factors, compared with the no-bronchiolitis hospitalization group, the bronchiolitis hospitalization group had a significantly higher rate of asthma (14% vs. 24%, HR = 2.77, 95%CI = 2.24–3.43, p < 0.001). There was significant heterogeneity by race and ethnicity (Pinteraction = 0.02). The magnitude of the association was greater in non-Hispanic White (HR = 3.77, 95%CI = 2.74–5.18, p < 0.001) and non-Hispanic Black (HR = 2.39, 95%CI = 1.60–3.56; p < 0.001) infants, compared with Hispanic infants (HR = 1.51, 95%CI = 0.77–2.95, p = 0.23). Conclusions: According to the nationwide cohort data, infants hospitalized with bronchiolitis are at a higher risk for asthma, with quantitative heterogeneity in different racial and ethnic groups.